The Purpose Of This Study Is To Evaluate The Effects Of An Investigational Medication On Depression Symptoms, Including Suicidal Thoughts.
Posted Date: Jan 15, 2020
- Investigator: Melissa Delbello
- Type of Study: Drug
A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Subjects Assessed to be at Imminent Risk for Suicide
12 To <18 Years Of Age, Diagnosed With Mdd Having Current Suicidal Thinking With Intent
Suicide, Depression, Kids
For More Information: